2025Year8Month1Day，Cardiovascular DevicesInnovative EnterpriseOrchestra BioMed(Nasdaq Code:OBIO) officially announced that it has completed a total scale of approximately4000Million USD Underwritten Public Offering Pricing,And CollaboratorsMedtronic (Medtronic）Will be further intensified3000Million USD`, raising over`7000Million USD funds（Approximately RMB5100 million), specifically for advancing the clinical development and commercialization of its core cardiovascular therapies.

Dual Empowerment of Capital and Resources

Accelerate the Implementation of Core Pipeline

According to the announcement,Orchestra BioMedPer Share2.75Completed this public offering at the price of XX dollars, with the issuance scale exceeding...940tens of millions of ordinary shares, with a total financing scale of approximately4000Million USD.The company made it clear that the proceeds will be used primarily to support its atrioventricular interval modulation (AVIM) Therapy andVirtueLate-stage clinical trials and commercialization preparations for the two core projects of Sirolimus-coated balloon catheters.

AsOrchestra BioMedA long-term partner,Medtronic Deepens Collaboration and Commits to Additional Investment in This Fundraising Round3000Million US dollars, including2000Million USD Loan Agreement and1000Ordinary Share Purchase Agreement in millions of US dollars。The scope of cooperation between the two parties has also expanded simultaneously:Medtronic Plans toAVIMTherapy integration into the development of its next-generation dual-chamber leadless pacemaker, exploring "blood pressure reduction+"Rhythm Management" Integrated Solution, aiming to provide better treatment options for patients with cardiovascular diseases.

At the same time,Orchestra BioMedAndLigand PharmaceuticalsReach a strategic cooperation, the latter will provide the former with through the transaction2000Million USD in immediate funding support, and plans to500Million US dollars to subscribe for company shares. In addition,LigandPreserve the Future9Additional within the month based on project milestone achievements1500Million-dollar investment options further demonstrate confidence in its technological potential and commercialization prospects.

Analysts pointed out that this fundraising and strategic cooperation not onlyOrchestra BioMedProvided critical funding support and further introduced Medtronic's global channel resources.Ligand's biopharmaceutical expertise, building a complete ecosystem from R&D to commercialization.Among the company's core products,AVIMTherapy has been approved by the EUCECertification,IIClinical trials show that it can significantly and continuously reduce blood pressure in hypertensive patients;VirtueVascular infusion balloon gains approval in the U.S.FDA"Breakthrough Device" designation, achieving stentless vascular repair through localized drug infusion, with significant market potential.

Orchestra BioMedChief Executive OfficerDavid HochmanSaid: "The completion of this fundraising and strategic cooperation marks a new stage in the company's development. We will make full use of the funds and partner resources to accelerate progress.AVIMTherapyIIIPhase Clinical andVirtue"The marketing application for the balloon, while deepening cooperation with Medtronic in the leadless pacemaker field, brings innovative treatment solutions to cardiovascular patients worldwide."

But after announcing the financing information,Orchestra BioMed The share price of2025 Year8 Month1 Plummeted in pre-market trading11.76%，Closing Price2.44Dollar, Down20.26%。Expressed market concerns about the company's later development.

"Technology Platform+"Giant Ecosystem"The Unique Path

Orchestra BioMedIs a U.S.Medical TechnologyInnovative Company, Founded in2017Year. Successively secured strategic investments from Medtronic and Terumo, two major international medical device giants.2023Year1Month, the company passedSPACModel ShellHealth Sciences Acquisitions Corporation 2Listed, Raised7000Million USD in funding.

The company owns twoCore Pipeline，Able toDual-Engine Driving Clinical Value Transformation：

BackBeat CNT: "Blood Pressure Revolution" in the Pacemaker Field

Global Super11Hundreds of millions of hypertension patients,70%Patients with implanted pacemakers simultaneously suffer from hypertension, while traditional pacemakers lack blood pressure regulation functionality.Orchestra BioMedJointly developed with MedtronicBackBeat CNT, by implantable device modulating the autonomic nervous system (ANS), to achieve24Hourly Dynamic Systolic Blood Pressure (aSBP) Net decrease8.1mmHg、Consulting Room Systolic Blood Pressure (oSBP) Net decrease12.3mmHgClinical Effect (MODERATO IIResearch data).

The product has been approved by the EUCECertification. Medtronic not only provides clinical support but also exclusively enjoys commercialization rights.Orchestra BioMedWhich shares the market dividend through a revenue-sharing model.According to industry analysts' estimates, if we consider globally every year110Number of pacemaker implants,20%Based on penetration rate estimation, the peak sales of this product are expected to exceed10Billion US dollars.

Virtue SAB: "Scarless Treatment" in the Field of Vascular Intervention

For in-stent restenosis of coronary artery (ISR) and other complex arterial diseases, the company has innovatively developedVirtue SABBalloon system, through the slow release of Sirolimus (SirolimusEFR™) Achieve"Intervention without Implant"——The balloon can be completely removed after the operation, leaving no permanent residue.SABRETrials show that the productISRPatient3Annual Target Lesion Revascularization (TLR) Incidence rate dropped to0, ObtainFDA"Breakthrough Device"Recognition.

Terumo Corporation3000Million-dollar upfront payment to secure global exclusive partnership rights, and take on heavy asset links such as manufacturing and distribution.Orchestra BioMedWhile retaining the development rights in non-cardiovascular fields, a light-asset operation is achieved through a royalty-sharing model.According toLSIData,2019Global Vascular Intervention Surgeries Exceeded in ...780Ten thousand cases, if according to5%Penetration rate estimation shows that the potential market size of this product reaches20Billion US dollars.

Different from the independent research and development model of traditional medical device enterprises,Orchestra BioMedBuilt"Technology Platform+Giant Ecosystem"The Unique Path:

Technology Output: PassedSirolimusEFR™ Drug Sustained Release,ANSCore patented technologies such as modulation complement industry leaders;

Risk Sharing: Medtronic and Terumo not only provide funding but also deeply engage in critical aspects such as clinical design and regulatory approval;

Revenue Sharing: Adoption"Advance Payment+Milestone Payment+Sales Split"The three-dimensional return mechanism balances short-term cash flow with long-term value.

Orchestra BioMedThe case demonstrates that start-ups can strategically collaborate with industry giants by focusing on technological breakthroughs in niche areas. This model not only reduces R&D risks but also accelerates commercialization through the global channels of partners, providing a replicable path for innovative pharmaceutical and medical device companies.

Orchestra BioMedThrough "fundraising+"Double-Driven" Strategic Cooperation not only addresses the funding needs of late-stage clinical projects but also reduces commercialization risks by partnering with industry leaders. Medtronic andLigandThe additional investment also indirectly validates its technical barriers and market potential. Investors may focus on the clinical progress of its core products and the effectiveness of its technical integration with Medtronic.RelatedOrchestra BioMedFor further updates on its products, Instrumentation at Home will continue to monitor.